Trial Profile
Cardioprotective benefits of carvedilol-CR [controlled-release] or valsartan added to lisinopril in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Carvedilol (Primary) ; Lisinopril; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
- 24 May 2011 Results assessing efficacy under different cardiac loading conditions presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
- 30 Jun 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.